Postow, Michael

Publications

Sort by

Co-Author Network

selected publications

The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. Journal of translational medicine. 2020 Academic Article GET IT
Times cited: 1
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 151
TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Article GET IT
Times cited: 3
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 150
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma research. 2020 Academic Article GET IT
Times cited: 22
Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Editorial Article GET IT
Times cited: 1
First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 175
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. Ophthalmology. 2019 Academic Article GET IT
Times cited: 23
Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 186
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. 2018 GET IT
Times cited: 105
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 971
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science translational medicine. 2018 Academic Article GET IT
Times cited: 170
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 339
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer medicine. 2018 Academic Article GET IT
Times cited: 91
The brim of uncertainty in adjuvant treatment of melanoma. The Lancet. Oncology. 2018 Article GET IT
Times cited: 2
Participatory implementation science to increase the impact of evidence-based cancer prevention and control. Cancer causes & control : CCC. 2018 Academic Article GET IT
Times cited: 116
Reply to M. Horiguchi et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Article GET IT
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Academic Article GET IT
Times cited: 339
High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 Academic Article GET IT
Times cited: 268
Clinical Development of PD-1 in Advanced Melanoma. Cancer journal (Sudbury, Mass.). 2018 Information Resource GET IT
Times cited: 41
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Journal of immunotherapy (Hagerstown, Md. : 1997). 2017 Academic Article GET IT
Times cited: 16
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. Journal for immunotherapy of cancer. 2017 Academic Article GET IT
Times cited: 94
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget. 2017 Academic Article GET IT
Times cited: 9
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2017 Academic Article GET IT
Times cited: 2823
Treatment of advanced melanoma - A changing landscape. Revista da Associacao Medica Brasileira (1992). 2017 Information Resource GET IT
Times cited: 13
Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 17
Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?. The Lancet. Oncology. 2017 Article GET IT
Times cited: 3
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. Ophthalmology. 2017 Academic Article GET IT
Times cited: 102
Health-related quality of life results from the phase III CheckMate 067 study. European journal of cancer. 2017 Academic Article GET IT
Times cited: 76
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer treatment reviews. 2017 Information Resource GET IT
Times cited: 134
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017 Academic Article GET IT
Times cited: 1233
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. EBioMedicine. 2017 Academic Article GET IT
Times cited: 83
Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. Annals of surgical oncology. 2017 Academic Article GET IT
Times cited: 35
Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017 Academic Article GET IT
Times cited: 19
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European journal of cancer. 2017 Academic Article GET IT
Times cited: 83
Better use of immune checkpoint inhibition: Treating higher risk patients and examining neurologic toxicity. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Editorial Article GET IT
Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation. Cancer journal (Sudbury, Mass.). 2017 Information Resource GET IT
Times cited: 29
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. Journal of the National Cancer Institute. 2016 Academic Article GET IT
Times cited: 57
Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Article GET IT
Times cited: 22
Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment cell & melanoma research. 2016 Information Resource GET IT
Times cited: 98
Recent advances in understanding antitumor immunity. F1000Research. 2016 Information Resource GET IT
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 19
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA oncology. 2016 Information Resource GET IT
Times cited: 387
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 878
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 779
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Academic Article GET IT
Times cited: 286
The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Academic Article GET IT
Times cited: 246
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Academic Article GET IT
Times cited: 229
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European journal of cancer. 2016 Academic Article GET IT
Times cited: 59
Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. Experimental dermatology. 2016 Article GET IT
Times cited: 17
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. The oncologist. 2016 Academic Article GET IT
Times cited: 149
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma research. 2016 Academic Article GET IT
Times cited: 33
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016 Information Resource GET IT
Times cited: 133
Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016 Information Resource GET IT
Times cited: 279
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 468
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 147
Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head & neck. 2016 Academic Article GET IT
Times cited: 70
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. Current oncology reports. 2016 Information Resource GET IT
Times cited: 39
Reply to N. Lowy et al and to J. Dhanda et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Article GET IT
Irradiation and immunotherapy: From concept to the clinic. Cancer. 2016 Information Resource GET IT
Times cited: 49
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 458
Reply to A. Indini et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Article GET IT
Checkpoint Blockade for the Treatment of Advanced Melanoma. Cancer treatment and research. 2016 Article GET IT
Times cited: 33
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. 2015 Academic Article GET IT
Times cited: 190
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 869
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. British journal of haematology. 2015 Academic Article GET IT
Times cited: 15
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. Journal for immunotherapy of cancer. 2015 Academic Article GET IT
Times cited: 182
Liver resection and ablation for metastatic melanoma: A single center experience. Journal of surgical oncology. 2015 Academic Article GET IT
Times cited: 21
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 6120
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 2361
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science translational medicine. 2015 Information Resource GET IT
Times cited: 100
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. International journal of radiation oncology, biology, physics. 2015 Academic Article GET IT
Times cited: 321
Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. American journal of clinical oncology. 2015 Information Resource GET IT
Times cited: 61
Immune Checkpoint Blockade in Cancer Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Information Resource GET IT
Times cited: 2217
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell research. 2015 Academic Article GET IT
Times cited: 127
Immune checkpoint modulation: rational design of combination strategies. Pharmacology & therapeutics. 2015 Information Resource GET IT
Times cited: 65
Managing immune checkpoint-blocking antibody side effects. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Information Resource GET IT
Times cited: 270
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 93
Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 3465
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics and personalized medicine. 2014 Information Resource GET IT
Times cited: 104
CTLA-4 antibodies: new directions, new combinations. Oncology (Williston Park, N.Y.). 2014 Information Resource GET IT
Times cited: 20
Ipilimumab in patients with melanoma and autoimmune disease. Journal for immunotherapy of cancer. 2014 Academic Article GET IT
Times cited: 87
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (London, England). 2014 Academic Article GET IT
Times cited: 1275
Opportunistic infections in patients treated with immunotherapy for cancer. Journal for immunotherapy of cancer. 2014 Academic Article GET IT
Times cited: 98
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 114
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. International journal of radiation oncology, biology, physics. 2014 Information Resource GET IT
Times cited: 134
Current options and future directions in the systemic treatment of metastatic melanoma. The Journal of community and supportive oncology. 2014 Academic Article GET IT
Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma. Methods in molecular biology (Clifton, N.J.). 2014 Academic Article GET IT
Times cited: 7
Immune modulation in cancer with antibodies. Annual review of medicine. 2013 Information Resource GET IT
Times cited: 328
Checkpoint blocking antibodies in cancer immunotherapy. FEBS letters. 2013 Information Resource GET IT
Times cited: 191
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Academic Article GET IT
Times cited: 163
Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer immunology research. 2013 Information Resource GET IT
Times cited: 130
Nivolumab plus ipilimumab in advanced melanoma. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 3563
Ipilimumab for patients with advanced mucosal melanoma. The oncologist. 2013 Academic Article GET IT
Times cited: 135
Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. Clinical sarcoma research. 2012 Academic Article GET IT
A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management. 2012 GET IT
Times cited: 1
Abscopal effect in a patient with melanoma. The New England journal of medicine. 2012 Letter GET IT
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer journal (Sudbury, Mass.). 2012 Information Resource GET IT
Times cited: 60
Therapeutic implications of KIT in melanoma. Cancer journal (Sudbury, Mass.). 2012 Information Resource GET IT
Times cited: 29
Causes and consequences of microRNA dysregulation. Cancer journal (Sudbury, Mass.). 2012 Review GET IT
Times cited: 255
Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer journal (Sudbury, Mass.). 2011 Information Resource GET IT
Times cited: 25

more ...

less ...

Background

education and training

B.S., Duke University 2008
M.D., New York University School of Medicine 2007

Contact

full name

Michael Postow

VIVO Weill Cornell Medical College

Michael Postow Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name